Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Scientists discover sign of early development of pancreatic cancer

Scientists discover sign of early development of pancreatic cancer

Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer - an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear. [More]
Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Bacterial communication molecules can be manipulated to prevent cancer cells from spreading

Bacterial communication molecules can be manipulated to prevent cancer cells from spreading

Cancer, while always dangerous, truly becomes life-threatening when cancer cells begin to spread to different areas throughout the body. [More]
Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Analysis of circulating tumor cells (CTCs) in a mouse model of pancreatic cancer identified distinct patterns of gene expression in several groups of CTCs, including significant differences from the primary tumor that may contribute to the ability to generate metastases. [More]
Disrupting cancer regulator MYC: an interview with Professor Kim Janda

Disrupting cancer regulator MYC: an interview with Professor Kim Janda

MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC’s tertiary structure is intrinsically disordered and the protein is transcriptionally inactive. [More]
Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers. [More]
KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

There is an urgent need for medical agents to treat metastatic tumors. In case of pancreatic cancer, one of the most aggressive types of cancer that is often detected late, 95% of the patients die within five years after the diagnosis. [More]
State highlights: Calif. hospital accused of patient dumping; Wash. mental health changes

State highlights: Calif. hospital accused of patient dumping; Wash. mental health changes

Los Angeles City Atty. Mike Feuer has filed a lawsuit accusing Glendale Adventist Medical Center of dumping mentally ill and disabled homeless patients on L.A.'s skid row over the last four years. The six-page complaint, filed Wednesday in Los Angeles County Superior Court, said the hospital improperly transported elderly and dependent patients to the downtown Los Angeles neighborhood, a 50-block area "known for extreme poverty, homelessness, rampant sale and use of illegal drugs and violent crime" (Holland, 8/22). [More]
Study links gum disease to lung disease, cancer and heart failure

Study links gum disease to lung disease, cancer and heart failure

Most people are very familiar with the reality that, if they don't practice regular brushing and overall good dental hygiene, they are at risk for developing gum disease. Less well known is the full extent of the potential harm caused by gum disease. [More]
Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine. [More]
Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These troublesome spots lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment using bacteria that thrive in oxygen-poor conditions. [More]
Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share. [More]

Cancer Research UK, CRT and Astellas collaborate to find new drug targets for pancreatic cancer

Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer. [More]
Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014. [More]
Long-term survival from pancreatic cancer fails to improve in 40 years

Long-term survival from pancreatic cancer fails to improve in 40 years

Long-term survival from pancreatic cancer has failed to improve in 40 years - with the outlook remaining the lowest of the 21 most common cancers, according to new figures published by Cancer Research UK today. [More]
New genetic markers signal increased risk of developing pancreatic cancer

New genetic markers signal increased risk of developing pancreatic cancer

A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, report scientists from Dana-Farber Cancer Institute. [More]
New use for old drug provides hope for patients with pancreatic cancer

New use for old drug provides hope for patients with pancreatic cancer

Cancer Research UK scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumour and stops it spreading, according to research published in Gut. [More]
CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil. [More]
Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer. [More]
Saltier intravenous drip reduces overall rate of complications by 25% after Whipple surgery

Saltier intravenous drip reduces overall rate of complications by 25% after Whipple surgery

Adequate hydration via a saline drip is essential during surgery, but recent reports suggest that getting the balance of salt and water just right could have an important impact on patient recovery. [More]